NRXP · NRX Pharmaceuticals, Inc.

NasdaqHealthcareBiotechnology

Nrx Pharmaceuticals Inc Is A Clinical-Stage, Small-Molecule Pharmaceutical Company That Develops And Plans To Distribute Novel Therapeutics For The Treatment Of Central Nervous System Disorders And Life-Threatening Pulmonary Diseases. The Company Is Developing Nrx-100/101, The First Sequential Drug Regimen For Bipolar Depression In Patients With Acute Suicidal Ideation And Behavior.

HealthcareNasdaqUSMid Float

$4.15

+34.7% latest move

Price & move as of the most recent catalyst (Aug 7) — not a live quote.

FLOAT

31.0M

FREE FLOAT %

72%

SHARES O/S

43.3M

MARKET CAP

$123.4M

EXCHANGE

Nasdaq

COUNTRY

NRXP Catalyst History

Regulatory and ClinicalFDA ApprovalAug 7, 2026 · 7:59am ET

NRXPNRX Pharmaceuticals, Inc.

NRx Pharmaceuticals Receives FDA First-Cycle Review Completion for Preservative-Free Ketamine ANDA

Company awaits final packaging certification for approval.

Be early on the next NRXP spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

NRXP · NRX Pharmaceuticals, Inc.

NRXP Catalyst History

NRx Pharmaceuticals Receives FDA First-Cycle Review Completion for Preservative-Free Ketamine ANDA

NRx Pharmaceuticals Receives FDA First-Cycle Review Completion for Preservative-Free Ketamine ANDA

NRx Pharmaceuticals and Hope Therapeutics Announce Acquisition of Kadima Neuropsychiatry Institute

NRx Pharmaceuticals and Hope Therapeutics Announce Acquisition of Kadima Neuropsychiatry Institute